Revolut plans a dual London and Nasdaq listing, Storonsky tells Les Echos
THE SO WHAT
Revolut targeting a dual London–Nasdaq listing is a bid to capture US liquidity without abandoning UK roots—fintechs are optimizing for both regulatory familiarity and valuation. Late-stage European startups should revisit where their eventual listing narrative actually resonates with investors and customers.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureSoftBank agrees to acquire Robotics and AI Institute
SoftBank consolidating a research-heavy robotics and AI asset under CFIUS review shows frontier autonomy is now squarely in the national-interest bucket. If your roadmap depends on cross-border capital or talent in advanced robotics, assume more friction and longer timelines on strategic deals.
Startups & VentureUK Sovereign AI Fund in talks to back £500m raise for drug discovery startup
If the UK’s sovereign AI vehicle is anchoring a £500m raise into drug discovery, national AI strategy is moving from chips and models into domain-specific IP. Biotech operators should expect more state-backed AI competitors and tighter competition for top applied ML talent.
Startups & VentureManus seeks $4B valuation in new $500M fundraise as it resumes independent ops
A $4B target valuation and $500M raise for Manus, post-terminated merger, shows capital still believes in independent AI platforms rather than pure acqui-hires. If you’re a mid-stage AI company, this is a green light to pursue scale on your own terms—but expect investors to push hard on defensibility and unit economics.
Startups & VentureImmunology Drugmaker Electra Opens Flat After Upsized US IPO
Electra Therapeutics raising $350m in an upsized IPO but trading flat suggests public markets will fund late-stage biotech, but without the 2021-style pop. Biotech operators should plan for capital access with muted aftermarket enthusiasm—story and pipeline depth matter more than listing optics.